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Human ESCRT-I is a multiprotein complex that
plays essential roles in HIV budding and endo-
somal protein sorting. All ESCRT-I complexes
contain three common subunits (TSG101,
VPS28, and VPS37), and a fourth subunit of
yeast ESCRT-I was recently identified
(Mvb12p).Wenowdemonstrate that two related
human proteins (MVB12A and MVB12B) consti-
tute the fourth class of metazoan ESCRT-I
subunits, despite lacking identifiable sequence
homology to Mvb12p. Hydrodynamic studies
indicate that soluble human ESCRT-I com-
plexes contain one copy of each of the four
subunit types. MVB12 subunits associate with
the core region of the binary TSG101-VPS37
complex through conserved C-terminal
sequence elements. Both MVB12 depletion
and overexpression inhibit HIV-1 infectivity
and induce unusual viral assembly defects,
including aberrant virion morphologies and
altered viral Gag protein processing. Taken
together, these studies define the composition
of human ESCRT-I complexes and indicate
that the MVB12 subunits play a unique role in
regulating ESCRT-mediated virus budding.
INTRODUCTION
Human ESCRT-I (endosomal sorting complex required for
transport-I) is a multiprotein complex that helps sort
membrane proteins into vesicles that bud into late endoso-
mal compartments calledmultivesicular bodies (MVB) (Gill
et al., 2007b; Gruenberg and Stenmark, 2004; Hurley and
Emr, 2006). ESCRT-I also mediates the budding of HIV-1
andother envelopedRNAviruses (Bieniasz, 2006;Demirov
and Freed, 2004; Morita and Sundquist, 2004). Hence,
ESCRT-I plays essential roles in several significant biolog-
ical processes, including the release of human pathogens
and the essential downregulation of cell surface receptors
targeted for lysosomal degradation via MVB vesicles.CUnder steady state conditions, ESCRT-I is distributed
throughout the cytoplasm, but is transiently recruited to
sites of MVB vesicle and virus budding (Katzmann et al.,
2001; Martin-Serrano et al., 2001; Welsch et al., 2006).
ESCRT-I is recruited to function in HIV-1 budding via
direct interactions with the PTAP ‘‘late domain’’ sequence
located within the p6 region of the viral Gag polypeptide.
Gag is the major viral structural protein and has the intrin-
sic ability to bind membranes and assemble into spherical
particles, but requires the ESCRT-I interaction to accom-
plish the membrane fission required for efficient virion
release. Virion budding initiates viral maturation, a step-
wise process that involves (1) activation of the viral prote-
ase; (2) proteolytic cleavage of Gag at a series of different
sites to liberate the mature MA, CA, and NC proteins; and
(3) major structural rearrangements involving condensa-
tion of the NC-RNA complex and assembly of CA into
the conical capsid that surrounds the NC-RNA complex.
In the endosomal pathway, ESCRT-I can be recruited to
function in MVB vesicle formation through direct interac-
tions with the upstream HRS/Vps27p protein complex
(Bache et al., 2003; Katzmann et al., 2003; Lu et al.,
2003; Pornillos et al., 2003). Once localized to the mem-
brane, ESCRT-I can bind ubiquitylated protein cargoes
and recruit downstream effector complexes such as
ESCRT-II and ESCRT-III that help mediate protein sorting
and vesicle formation. The assembled ESCRT complexes
are then recycled by the action of the VPS4 ATPases, the
only known enzymes in the pathway (Babst et al., 1998).
Human and yeast ESCRT-I complexes share at least
three homologous subunits, termed TSG101/Vps23p,
VPS28/Vps28p and VPS37/Vps37p. Structural and bio-
chemical analyses have revealed that the yeast Vps23p,
Vps28p, and Vps37p subunits form a 1:1:1 ternary com-
plex in which conserved segments from each subunit
coassemble into a six helix bundle (Chu et al., 2006; Gill
et al., 2007a; Kostelansky et al., 2006; Teo et al., 2006).
Each subunit contributes a helical hairpin, which associate
side-to-side along their long axes with the Vps23p hairpin
in the center. Outside of the helical bundle, the ESCRT-I
subunits display a series of ‘‘effector’’ domains that inter-
act with other protein binding partners. For example,
Vps23p/TSG101 has a predicated coiled-coil element
immediately upstream of the core hairpin that has been
implicated in protein oligomerization (Chu et al., 2006;
Martin-Serrano et al., 2003) and an N-terminal UEVell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc. 41
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mann et al., 2001; Sundquist et al., 2004; Teo et al., 2004)
and proline-rich elements such as the P(S/T)AP elements
in HIV-1 p6Gag and HRS/Vps27p (Pornillos et al., 2002).
The basic architecture of mammalian ESCRT-I appears
to be similar to that of yeast ESCRT-I because the
TSG101/Vps23p, VPS28/Vps28p, and VPS37/Vps37p
subunits have common domain organizations and related
sequences. Mammalian ESCRT-I complexes exhibit
greater complexity, however, as mammalian cells express
four different, but related, VPS37 subunits (termed
VPS37A-D) (Bache et al., 2004; Eastman et al., 2005;
Stuchell et al., 2004). Each different VPS37 protein con-
tains a region of 150 amino acids that includes theminimal
TSG101-binding element and is related in sequence to
yeast Vps37p. The different mammalian VPS37 proteins
diverge significantly outside of this conserved region,
however, which may allow them to interact with distinct
cellular binding partners.
Recently, several groups have characterized a fourth
subunit of the yeast ESCRT-I complex, termed Mvb12p
(Chu et al., 2006; Curtiss et al., 2007; Gill et al., 2007a;
Oestreich et al., 2007). Metazoan homologs of Mvb12p
have not yet been identified, although Chu et al. have
noted weak sequence similarities between Mvb12p and
human apolipoprotein O (Chu et al., 2006). As part of our
continuing effort to characterize human ESCRT-I and its
role in HIV-1 budding and assembly, we have searched
for cellular proteins that bind ESCRT-I. Here, we report
the identification and characterization of a fourth class of
proteins that function as stable, constitutive subunits of
human ESCRT-I and are required for efficient HIV-1
assembly and infectivity.
RESULTS
Identification of MVB12A as a Binding Partner
for the Human ESCRT-I Complex
The six known human ESCRT-I subunits (One-STrEP-
FLAG (OSF)-TSG101, VPS28, and VPS37A-D) were simul-
taneously coexpressed in 293T cells to create ‘‘baits’’ that
could be used to identify ESCRT-I binding proteins. The
resulting mixture of ESCRT-I complexes was affinity puri-
fied on a Strep-Tactinmatrix, which captured TSG101 and
stable binding partners. Bound proteins were analyzed by
SDS-PAGE (Figure 1A, lane 2), and the ESCRT-I subunits
were identified by comparison to known standards. As
expected, the tagged TSG101 subunit and the five other
overexpressed ESCRT-I subunits were substantially
enriched by this procedure. In addition, a seventh endog-
enous protein with a molecular mass of 30 KDa repro-
ducibly copurified with the ESCRT-I complexes (denoted
‘‘?’’ in Figure 1A, lane 2). This protein was identified by
in-gel trypsin digestion and mass spectrometry analyses,
which produced eight different peptides, matching those
predicted for NCBI protein NP_612410 (273 residues,
41% coverage, see Table S1), which is hereafter called
MVB12A (multivesicular body subunit 12A). Database
and literature searches revealed thatMVB12Awas a previ-42 Cell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc.ously uncharacterized protein of unknown function and
also identified a second related human protein of 319
residues (MVB12B) that shared 30% sequence identity
with MVB12A (NCBI protein NP_258257, Figure S1).
In addition to MVB12A, a series of other endogenous
proteins copurified with the OSF-TSG101-VPS37-VPS28
complexes, albeit at lower levels. To test whether endog-
enous MVB12B was one of these copurifying proteins,
a gel section spanning the expected mass of MVB12B
(30–40 KDa) was excised and analyzed by trypsin diges-
tion and mass spectrometry. This experiment confirmed
the presence of MVB12B in the affinity purified mixture
(4 peptides, 38% coverage, Table S1). Hence, both
MVB12A and MVB12B proteins were expressed in 293T
cells, and both coaffinity purified with overexpressed
ESCRT-I complexes, indicating that these two proteins
might be ESCRT-I subunits or binding partners.
In related experiments, Strep-tagged versions of each
of the different ESCRT-I proteins were also expressed
singly, and trypsin digestion and mass spectrometry
were again used to identify other ESCRT-I subunits that
copurified by Strep-Tactin affinity chromatography (Table
S1). Pairwise interactions between MVB12 proteins and
other ESCRT-I subunits were observed 21 different times
in these experiments, further confirming that MVB12A and
MVB12B associate with the other ESCRT-I subunits in
vivo. In contrast, apolipoprotein O, a previously proposed
candidate for the mammalian homolog of yeast Mvb12p
(Chu et al., 2006), was not detected in any of our proteo-
mics studies.
MVB12A Binds All Possible Human ESCRT-I
Complexes
To test whether MVB12A could form stable stoichiometric
complexes with the other three ESCRT-I subunits, Myc-
MVB12A was co-overexpressed together with OSF-
TSG101, VPS28, and VPS37B, and complexes were again
affinity purified on a Strep-Tactin matrix. As shown in
Figure 1B, equivalent levels of VPS28, VPS37B, and
MVB12A copurified with OSF-TSG101 (lane 2), but did
not bind a control matrix (lane 1), indicating that the
interactions were specific and were mediated by
TSG101. In reciprocal experiments, equivalent levels of
Myc-TSG101, VPS28, and Vps37B copurified with OSF-
MVB12A (lane 4), and again did not bind the matrix control
(lane 3). Thus, MVB12A forms stable quaternary com-
plexes with TGS101, VPS28, and VPS37B in human cells.
Analogous experiments performed for MVB12B showed
that TSG101, VPS28, and VPS37B also formed stable
complexes with MVB12B (Figure S2A, lanes 2 and 4)
without background binding to control matrices (lanes 1
and 3).
We also tested the possibility that specific VPS37 sub-
units might uniquely pair with specific MVB12 subunits.
This was not the case, however, as all four known human
VPS37 subunits (VPS37A-D) formed stable quaternary
complexes with TSG101-VPS28-MVB12A (Figure 1C,
lanes 1-4) and with TSG101-VPS28-MVB12B
(Figure S2B). Thus, human cells express multiple paralogs
Cell Host & Microbe
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plexes
(A) Affinity purification and analysis of Strep-tagged TSG101/ESCRT-I
complexes. All six previously known human ESCRT-I subunits (One-
STrEP-FLAG (OSF)-TSG101, VPS28, VPS37A–D) were simultaneously
coexpressed in 293T cells. The resulting complexes were affinity puri-
fied on a Strep-Tactin matrix and visualized by SDS-PAGE (lane 2,
Coomassie staining). ESCRT-I subunits coaffinity purifying with OSF-
TSG101 are labeled at right, and the band labeled ‘‘?’’ was identified
as MVB12A (NCBI: NP_612410). Lane 1 shows background proteinCof both VPS37 and MVB12, and all 8 possible combina-
tions of human ESCRT-I subunits assemble into stable
complexes in human cells.
MVB12A Binds ESCRT-I through Its Conserved
C Terminus
Deletion analyses were used to map the ESCRT-I binding
site(s) on the MVB12 proteins. A summary of the different
MVB12 constructs employed in these studies is provided
in Figure S3. As shown in Figure 2A, an MVB12A fragment
lacking the final 40 residues (MVB12A1–233) formed a
stable complex with the other three ESCRT-I proteins
(lane 3), whereas a construct lacking the final 82 residues
(MVB12A1–191) did not (lane 4). Conversely, an MVB12A
fragment consisting of only the final 82 residues
(MVB12A192–273) formed a stable ESCRT-I complex (lane
5), demonstrating that the C-terminal region of MVB12A
was necessary and sufficient for ESCRT-I binding. The
interaction site could not be subdivided further, however,
as two nonoverlapping C-terminal fragments of MVB12A
(MVB12A192–233 and MVB12A234–273) both bound
ESCRT-I (lanes 6 and 7). Hence, MVB12A must contact
ESCRT-I through at least two adjacent sites, one located
within residues 192–233 and a second within residues
234–273 (termed ESCRT-I-binding boxes 1 and 2, abbre-
viated EBB1 and EBB2). An alignment of metazoan
MVB12 proteins indicates that the sequence correspond-
ing toMVB12A residues 192–233 (EBB1) is themost highly
conserved region of the protein (Figure S1), and our map-
ping experiments indicate that this sequence conservation
reflects a conserved ESCRT-I binding function.
MVB12B exhibits additional complexity in that two
different splice isoforms of the protein have been identified
(NCBI FAM125B, GeneID no. 89853). The longer isoform 1
(MVB12B1–319) containsbothEBB1andEBB2,whereas the
shorter isoform 2 (MVB12B1–221) does not. Binding experi-
ments confirmed the expectation thatMVB12B1–319 bound
ESCRT-I, whereas MVB12B1–221 did not (Figure 2A, com-
pare lanes 9 and 10). Furthermore, a fragment of MVB12B
corresponding to the EBB1 alone (MVB12B227–271) again
binding levels from a control purification from cells transfected with
an empty vector.
(B) MVB12A forms a stable, stoichiometric complex with TSG101,
VPS28, and VPS37B. Lanes 2 and 4 show affinity purification of the
quaternary complex when the four proteins were coexpressed with
OSF-TSG101 (lane 2) or OSF-MVB12A (lane 4). Asterisks here and
throughout denote the tagged ‘‘bait’’ protein. Lanes 1 and 3 show
control experiments with extracts that lacked the OSF-tagged subunit.
(Upper panel) SDS-PAGE gel showing all copurifying proteins (Coo-
massie staining). (Lower panels) Western blot (anti-Myc) detection of
Myc-MVB12A (lanes 1 and 2) or Myc-TSG101 (lanes 3 and 4) bound
to the Strep-Tactin matrix (middle panel) or in the input lysate (lower
panel). Note that MVB12A migration changes with the presence or
absence of the affinity tag.
(C) MVB12A forms stable, stoichiometric ESCRT-I complexes with all
four known VPS37 subunits. SDS-PAGE gel (Coomassie staining)
showing the proteins that coaffinity purify with OSF-TSG101 from
lysates containing overexpressed OSF-TSG101, VPS28, MVB12A,
and one of the following: Vps37A (lane 1), Vps37B (lane 2), Vps37C
(lane 3), and Vps37D (lane 4).ell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc. 43
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(A) Deletion analysis showing the minimal ESCRT-I binding regions on MVB12A and MVB12B. Upper panel shows binding of the TSG101-VPS28-
VPS37B ESCRT-I ternary complex to a deletion series of OSF-MVB12A (lanes 2–7) and OSF-MVB12B (lanes 9–11). Lanes 1 and 8 show background
ESCRT-I binding in the absence of the OSF-MVB12 subunit (negative controls). Proteins were visualized by Coomassie staining, and OSF-MVB12
‘‘baits’’ are designated with asterisks. The lower panel shows a western blot of the input lysates (anti-Myc), confirming the presence of Myc-TSG101.
(B) MVB12A binds binary TSG101-VPS37 complexes. Copurification of Myc-MVB12A with different OSF-tagged and untagged ESCRT-I subunits
(indicated above). (Upper panel) Western blots testing Myc-MVB12A binding to different ESCRT-I subunits and subcomplexes. (Lower and middle
panels) Control western blots confirming expression of MVB12A (middle) and OSF-tagged protein binding to the Strep-Tactin matrix (lower). Controls
show lack of Myc-MVB12A binding in the absence of other ESCRT-I subunits (negative control, lane 1), and Myc-MVB12A binding to the TSG101-
VPS28-VPS37 ternary complex (positive control, lane 11).
(C) Deletion analysis mapping of the minimal MVB12A binding sites on TSG101 and VPS37B. SDS-PAGE gel (Coomassie staining) showing copur-
ification of full-length Myc-MVB12A with different OSF-tagged TSG101 and VPS37B constructs. OSF-tagged baits are given above and are desig-
nated by asterisks. (Lower panel) Control western blot of the input lysates, confirming the presence of Myc-MVB12A. (Middle panel) Western blot of
the purified complexes (anti-Myc), confirming the presence or absence of Myc-MVB12A.
(D) Summary of the ESCRT-I core interaction sites for TSG101, VPS28, VPS37, and MVB12. Core binding regions of TSG101, VPS28, VPS37(A), and
MVB12(A) are shown in lighter shades.bound ESCRT-I (Figure 2A, lane 11), demonstrating that
MVB12B EBB1 was also an ESCRT-I binding module.
Thus, both MVB12A and MVB12B bind the ESCRT-I
complex through conserved C-terminal ESCRT-I Binding
Boxes, whereas a shorterMVB12B isoformmissing this re-
gion does not bind ESCRT-I.
MVB12A and MVB12B Bind the TSG101-VPS37
Binary Complex
To map the binding requirements on the ESCRT-I side of
the interaction, we first tested whether MVB12A could44 Cell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc.bind TSG101, VPS37B, or VPS28 alone. As shown in
Figure 2B,Myc-MVB12Adid not copurify at stoichiometric
levels with any of the four isolated OSF-tagged ESCRT-I
subunits (upper panel, lanes 2–4). We next tested whether
MVB12A could bind any of the possible binary complexes
of other ESCRT-I subunits (lanes 5–10). These experi-
ments revealed that MVB12A bound TSG101-VPS37B
subcomplexes (lanes 7 and 8), but none of the other
possible ESCRT-I binary complexes (lanes 5, 6, 9, and
10). Control experiments behaved as expected in that
MVB12A bound the ternary TSG101-VPS28-VPS37
Cell Host & Microbe
Composition of Human ESCRT-IFigure 3. Gel Filtration Chromatography
of ESCRT-I Complexes
(Panels 1 and 2) Gel filtration mobility and
homogeneity of endogenous ESCRT-I com-
plexes as detected by western blotting of
crude K562 cell lysates fractionated by gel
filtration chromatography and detected with
an anti-TSG101 antibody (Panel 1, apparent
MW 270 KDa) or an anti-MVB12A antibody.
(Panel 2, apparent MW 280 KDa). Assayed
fractions are given above, together with the
positions of molecular weight size markers.
Detection with anti-VPS28 and anti-VPS37B
antibodies yielded similar results (data not shown). Note that breaks between lanes reflect samples run on two different gels. (Panels 3–5) Gel filtration
mobilities and homogeneity of overexpressed ESCRT-I complexes from 293T cells. (Panel 3) Overexpressed OSF-TSG101-VPS28-VPS37B ternary
complexes (anti-FLAG detection, MWapp210 KDa), (Panel 4) OSF-TSG101-VPS28-VPS37B-Myc-MVB12A quaternary complexes (anti-Myc detec-
tion, MWapp 270). (Panel 5) OSF-TSG101-VPS28-VPS37B-Myc-MVB12B quaternary complexes (anti-Myc detection, MWapp 270 KDa).complex (lane11), but not thematrix alone (Figure 2B, lane 1).
These experiments imply that a binary TSG101-VPS37
complex is required to create a high affinity MVB12A bind-
ing site.
Deletion analyses were performed to map the regions of
TSG101 and VPS37B required for MVB12A binding. As
shown in Figure 2C, MVB12A binds the final 159 residues
of TSG101 (TSG101231–390), which spans the ESCRT-I core
(lanes 3 and 8). Similarly, MVB12A binding mapped to the
N-terminal half of VPS37B (VPS37B1–160, lanes 6 and 8),
which again corresponds to the most conserved region of
VPS37 and includes the minimal TSG101 binding site.
Thus, MVB12A binds the regions of TSG101 and VPS37
that form the ESCRT-I core (summarized in Figure 2D).
MVB12 Proteins Are Integral Components of Native
ESCRT-I Complexes
Endogenous mammalian ESCRT-I complexes reportedly
elute from gel filtration columns with an apparent molecu-
lar weight of 300-350 KDa (Babst et al., 2000; Stuchell
et al., 2004). This observation is recapitulated in Figure 3
(panel 1), where anti-TSG101 antibodies were used to fol-
low the gel filtration mobility of native ESCRT-I complexes
from crude soluble cell lysates. The apparent molecular
weight of human ESCRT-I was estimated to be 270–
280 KDa on this calibrated gel filtration column. To test
whether endogenous MVB12A is also a constitutive com-
ponent of ESCRT-I in human cells, anti-MVB12A anti-
bodies were raised and used to track the gel filtration
mobility of MVB12A. As shown in panel 2, essentially all
of the native MVB12A protein in the extract also precisely
coeluted with TSG101, as well as other ESCRT-I subunits
(data not shown). This experiment indicates that endoge-
nous MVB12A is stably associated with ESCRT-I.
Our attempts to perform analogous experiments with
MVB12B were unsuccessful because our anti-MVB12B
antibodies did not detect the endogenous protein. Never-
theless, the gel filtration experiments shown in Figure 3
demonstrate that when TSG101, VPS28, and VPS37B
were co-overexpressed with either MVB12A (panel 4) or
MVB12B (panel 5), the MVB12 proteins again elutedCfrom gel filtration columns in complexes with apparent
molecular weights of 270 KDa. These observations indi-
cate that both MVB12 paralogs quantitatively associate
with the other ESCRT-I subunits in cells. Moreover, these
exogenous ESCRT-I complexes exhibited the same gel
filtration mobilities as native, endogenous ESCRT-I
complexes (compare panels 1 and 2 to 4 and 5).
We also tested whether gel filtration mobility could be
used to distinguish ESCRT-I complexes that lacked
MVB12 subunits by examining the mobility of ESCRT-I
complexes from 293T cells in which only TSG101,
VPS37B, and VPS28 were highly overexpressed.
Although endogenous ESCRT-I subunits were still present
in these cells, the endogenous MVB12 subunits were lim-
iting, and the bulk of the tagged TSG101 in the cell was
therefore present in TSG101-VPS37B-VPS28 ternary
complexes. The apparent molecular weight of these ter-
nary complexes (MWapp210 KDa) was lower than that
of the quaternary ESCRT-I complexes, as assessed by fol-
lowing the elution of TSG101 (panel 3) or other ESCRT-I
subunits, (data not shown). The shift was modest (MWapp
60 KDa), however, and the TSG101 elution peak was
broadened, possibly owing to the presence of both
ternary and quaternary complexes, self-association of
the ternary complex, or overexpression effects. Impor-
tantly, the gel filtration mobility of native ESCRT-I com-
plexes (panels 1 and 2) matched that of the quaternary
TSG101-VPS37-VPS28/MVB12 complexes (panels 4
and 5) rather than the ternary TSG101-VPS37-VPS28
complexes (panel 3). This experiment indicates that
most (and perhaps all) endogenous cellular ESCRT-I com-
plexes contain MVB12 subunits, although we cannot rule
out the possibility that a minor pool of endogenous
ESCRT-I complexes may lack MVB12 subunits owing to
the limited resolution of the gel filtration experiment.
Recombinant ESCRT-I Complexes Bind HIV-1 p6Gag
and HRS
As discussed earlier, pure intact recombinant ESCRT-I
complexes from higher organisms have not been de-
scribed previously, both because MVB12 subunits hadell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc. 45
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(A) Purified recombinant ESCRT-I binds HIV-1 p6Gag and HRS. (Upper panels) Western blots detecting OSF-TSG101 (anti-Flag) or MVB12A (anti-
MVB12A). (Left panel) 2% of input ESCRT-I, (central panel) ESCRT-I binding to GST (negative control), wt HIV-1 p6Gag, or HIV-1 p6Gag P10A mutant,
(right panel) ESCRT-I binding to V5-HRS or to a mock purified control. Lower panels: SDS-PAGE (Coomassie staining) showing purified ESCRT-I (left
panel, 20% input), GST and GST-p6Gag fusion proteins (middle panel), and V5-HRS (right panel).
(B) The solution mass of the major complex of purified recombinant human ESCRT-I corresponds to a monomeric 1:1:1:1 complex of OSF-
TSG101:VPS37B:VPS28:MVB12A. The equilibrium sedimentation distribution of purified ESCRT-I complexes is shown (16,000 rpm, 3.6 mM
ESCRT-I, 4C). The black line shows the global fit of an ideal single species model to centrifugation data from two speeds and two protein concen-
trations (MWest = 130 KDa, MWmonomer = 134 KDa). For comparison, the distribution expected for a 2:2:2:2 dimeric ESCRT-I complex is shown in red.not been identified and because the proline-rich, N-termi-
nal half of TSG101/Vps23p is difficult to express in E. coli.
We therefore tested whether the mammalian coexpres-
sion system could be used to generate stable, full-length
recombinant ESCRT-I complexes for use in biochemical
and structural studies. As shown in Figure 4A (left panel),
milligram quantities of pure recombinant human ESCRT-I
could be generated by co-overexpressing all of the sub-
units in 293T cells, followed by affinity purification on
Strep-Tactin agarose and gel filtration chromatography.
ESCRT-I is recruited to sites of HIV-1 budding by the
viral p6Gag protein, and we therefore tested whether this
interaction could be recapitulated in vitro. As shown in
Figure 4A (middle panel), purified ESCRT-I bound wild-
type GST-p6Gag protein immobilized on glutathione aga-
rose, as detected in a western blot using anti-FLAG
(TSG101) antibodies (lane 2). This interaction appeared
to be specific because TSG101/ESCRT-I did not bind to
a control GST matrix (lane 1) or to an immobilized GST-
p6Gag protein with a point mutation in the key interacting
proline residue in the TSG101 binding site (p6Gag P10A,
lane 3). In cells, ESCRT-I can be recruited to sites of
MVB vesicle formation by the HRS complex. This interac-
tion could also be recapitulated in vitro using pure re-
combinant ESCRT-I and purified HRS, and the interaction
was again specific (Figure 4A, right panel). Thus, the
ESCRT-I interactions with p6Gag and HRS can be recapit-
ulated with pure recombinant proteins.
Soluble, Endogenous Human ESCRT-I Is a 1:1:1:1
Heterotetramer
Several lines of evidence suggest that TSG101 and
ESCRT-I have a propensity to self-associate in cells,46 Cell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc.and it has been proposed that Mvb12p stabilizes a
trimeric (or possibly dimeric) form of yeast ESCRT-I
(Chu et al., 2006). However, biophysical studies of pure
recombinant yeast ESCRT-I complexes indicate that re-
combinant Vps23p (TSG101), Vps28p, Vps37p, and
Mvb12p form a stable, 1:1:1:1 complex in solution (Gill
et al., 2007a). To date, there have been no reports of
the solution mass and stoichiometry of mammalian
ESCRT-I complexes.
Equilibrium sedimentation experiments were therefore
performed to determine the solution mass of purified
ESCRT-I complexes. The predominant form of affinity
purified, recombinant ESCRT-I eluted from a gel filtration
column with a MWapp 280–270 KDa (see Figure 3). A small
amount of recombinant ESCRT-I also eluted as a minor
peak of MWapp570 KDa (note that this minor species is
not visible in panel 1, and was not detected for endoge-
nous ESCRT-I). Analytical equilibrium sedimentation
data for the major recombinant ESCRT-I complex
matched that expected for a 1:1:1:1 complex of
TSG101:VPS28:VPS37B:MVB12A (Figure 4B, black curve),
but not for a 2:2:2:2 ‘‘dimeric’’ (red) or higher order
complexes. In contrast, the minor ESCRT-I species
was successfully modeled as a 2:2:2:2 ‘‘dimer’’ (Fig-
ure S4). Hence, the major soluble cellular ESCRT-I
species contains a single copy of each of the four dif-
ferent subunits. Importantly, the gel filtration mobility of
endogenous ESCRT-I complexes corresponded well to
the mobility of the recombinant 1:1:1:1 ESCRT-I com-
plex (compare panel 1 to panels 4 and 5 in Figure 3).
We therefore conclude that soluble endogenous human
ESCRT-I complexes extracted from cells contain single
copies of TSG101, VPS37, VPS28, and MVB12.
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as a Component of ESCRT-I
Under steady state conditions, ESCRT-I complexes are
transiently recruited to endosomal membranes, where
they function in MVB vesicle formation and are subse-
quently released by the action of the VPS4 ATPases
(Babst et al., 1997, 1998). Hence, ESCRT-I complexes
become trapped on aberrant endosomal compartments
(termed class E compartments) in the presence of domi-
nant negative VPS4 proteins that lack ATPase activity.
This system was therefore used to test whether MVB12A
was recruited to Class E compartments as a component
of ESCRT-I.
As shown in Figure 5A, epitope tagged WT MVB12A,
TSG101, and WT GFP-VPS4A were all distributed
throughout the cell when the three wild-type proteins
were co-overexpressed, together with untagged versions
of the other ESCRT-I subunits (upper row). MVB12A also
concentrated on centrosomes (see Figure S5). In contrast,
all three proteins became concentrated on punctate class
E compartments when the overexpressed VPS4A protein
lacked ATP-binding activity (VPS4A K173Q; middle row).
This marked redistribution of MVB12A correlated with
the ability of MVB12A to bind ESCRT-I, because a
truncated MVB12A protein that lacked the ESCRT-I
binding site (MVB12A1–191) failed to redistribute to class
E compartments (bottom row). These observations were
quantified by determining the degree of overlap between
the dominant-negative VPS4A K173Q protein and the
other proteins. As shown in Figure 5B, most of the WT
MVB12A in the cell colocalized with VPS4A K173Q (69 ±
11% colocalization), as did most of the WT TSG101 (70 ±
14% colocalization). In contrast, almost none of the
truncated MVB12A1–191 protein colocalized with VPS4A
K173Q (3.2 ± 1.6%) even though TSG101-VPS4A K173Q
colocalization was not significantly affected (60 ± 14%).
These experiments indicate that MVB12A is recruited to
endosomal membranes through its conserved C-terminal
ESCRT-I binding region and is then released from the
membrane by the activity of the VPS4 ATPase.
HIV-1 Infectivity, but Not Release, Is Reduced
upon MVB12 Depletion
ESCRT-I facilitates HIV-1 budding, and it was therefore of
interest to determine whether depletion of MVB12A and
MVB12B affects the late stages of HIV-1 replication. As
shown in Figure 6A, we identified two different siRNAs
that reduced the endogenousMVB12 protein to nearly un-
detectable levels (upper panel). Analogous experiments
could not be performed for MVB12B, however, owing to
our inability to detect the endogenous protein in western
blots. Nevertheless, we did identify two different siRNAs
that could efficiently deplete exogenously expressed
Myc-MVB12B (lower panel). As shown in Figure 6B, dif-
ferent combinations of the anti-MVB12 siRNA oligo-
nucleotides reduced infectious viral titers 2–5 fold. These
experiments indicate that normal cellular levels of MVB12A
and MVB12B are required for full HIV-1 infectivity.CSomewhat surprisingly, the phenotypic consequences
of MVB12 depletion differed in several respects from
depletion of TSG101 (positive control, last lane). First,
MVB12 depletion did not reduce viral infectivity to the
same extent as TSG101 depletion (42-fold reduction),
suggesting that the MVB12 subunits of ESCRT-I may not
play as central a role in HIV-1 budding as the TSG101
subunit. Second, MVB12 protein depletion did not mea-
surably reduce HIV-1 particle production, as judged by
western blotting of particle-associated CA and MA
proteins released into culture supernatants (Figure 6B,
middle panel). Thus, the reduction in viral infectivity seen
upon depletion of MVB12 proteins was not explained by
a proportional reduction in virus budding.
EM analyses were therefore performed to test whether
virions released in the absence of MVB12 proteins
exhibited an observable morphological defect that might
explain their reduced infectivity. As expected, HIV-1 parti-
cles released from wild-type cells frequently exhibited
conical capsids, which is the hallmark of mature virions.
As summarized in Figure 6C, mature HIV-1 capsids were
observed in just over half of the control particles examined
(52%). In contrast, depletion of either MVB12A or
MVB12B reduced the frequency of mature HIV-1 particles
by approximately 2-fold (29% and 27%, respectively) as
compared to the wild-type control, and instead resulted
in the production of an abnormally large number of
aberrant particles. These particles were described as
‘‘amorphous’’ because the virion interiors were highly
electron-dense throughout and lacked clearly defined
internal structures (see Figure 6C, lower right panel).
Amorphous particles accounted for only about 10% of
the virions produced from wild-type cells, but much
greater percentages of virions produced from MVB12A
or MVB12B-depleted cells (29% and 47%, respectively).
Hence, the reduced viral infectivity observed upon
MVB12 depletion correlated with reduced production of
mature virions and increased production of abnormal
virions. Although we do not know what causes the aber-
rant virion interiors to appear so amorphous, we speculate
that additional cellular proteins may be packaged within
these particles, thereby increasing their density and
obscuring the visualization of normal internal structures.
This is suggested in the ‘‘gradient’’ of amorphous particle
morphologies shown in Figure 6C, where internal core
structures appear evident beneath the obscuring density
within the lightest particles.
MVB12 Overexpression Reduces Virus Release,
Gag Processing, and Viral Infectivity
Previous studies have established that overexpression of
TSG101 (and TSG101 fragments) dominantly inhibits
HIV-1 release and infectivity, presumably by altering the
stoichiometry and/or activity of endogenous ESCRT-I
complexes (Figure 7A, compare lanes 1 and 6) (Shehu-
Xhilaga et al., 2004). As shown in Figure 7B, TSG101 over-
expression induced a ‘‘late domain’’ phenotype in which
assembling particles frequently remained tethered to the
cell through membrane stalks. The interiors of theseell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc. 47
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Composition of Human ESCRT-IFigure 5. Mutant VPS4 Proteins Relocal-
ize TSG101 and MVB12A to Class E MVB
Compartments
(A) Confocal immunofluorescence z slices
showing colocalization of different OSF-
MVB12A (red), Myc-TSG101 (blue) and VPS4A-
GFP (green)proteins (note thatuntaggedVPS28
andVPS37Bwerealsoco-overexpressed). (Top
row) Colocalization of the wild-type proteins.
(Middle row) Colocalization with a VPS4A
ATPase binding mutant (VPS4K173Q). (Lower
row) Colocalization with VPS4AK173Q, and a
truncated MVB12A protein (MVB12A1-191) that
lacked the ESCRT-I binding site. Merged im-
ages are shown in column 4, with white indicat-
ing full colocalization, and DIC images are
shown in column5. Scale bars represent 10 mM.
(B) Quantification of the percentage colocaliza-
tion of VPS4AK173Q with MVB12A or TSG101 in
the presence of WT MVB12A or MVB12A1–191
(n = 20 cells/data point). Error bars represent
standard deviations.tethered particles were frequently abnormally dense and
amorphous, which was reminiscent of the ‘‘amorphorous’’
phenotypes observed in virions produced from MVB12-
depleted cells. Overexpression of both MVB12A and
MVB12B also strongly inhibited HIV-1 infectivity (12- and
15-fold, respectively, Figure 7A left panel) with parallel
reductions in virion release (Figure 7A, right panel). These
reductions in virus release and infectivity were at least
partially relieved, however, when the overexpressed
MVB12A and MVB12B proteins lacked C-terminal
ESCRT-I-binding boxes (compare lanes 2 to 3 and lanes
4 to 5), indicating that ESCRT-I-binding activity was
required for full inhibition.
Once again, the phenotype of the HIV-1 assembly block
induced byMVB12 overexpression was unusual in several
respects. First, overexpression of MVB12A or MVB12B
proteins reduced the levels of intact Gag polyproteins in
producer cells only slightly (to 71 ± 8% of control for
MVB12A), but dramatically reduced the accumulation of
the intracellular MA and CA proteolytic processing prod-
ucts (to 11 ± 3% of control for MVB12A, see Figure 7A,
right middle panel and figure caption). In spite of the
strong reduction in particle release caused by MVB12
overexpression, however, the particles that were released
had fully processed MA and CA proteins, indicating that48 Cell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc.Gag was processed in those particles that escaped the
cell. EM analyses of the cell-associated viral particles pro-
duced in the presence of high levels of MVB12A revealed
an additional assembly/budding defect. As shown in
Figure 7B, viral particles produced in cells that overex-
pressed MVB12A frequently remained cell-associated.
Unlike the case of TSG101 overexpression, however,
most of these virions were not directly connected to the
cell membrane, though they were frequently tethered to
one another (and perhaps ultimately to the plasma mem-
brane) through continuous lipid bridges. The tethered
virions lacked mature conical capsids, and bore some
resemblance to immature viral particles, but with less
well-delineated Gag shells.
Mutation of MVB12A Phosphorylation Sites Partially
Relieves the Overexpression Block
Endogenous MVB12A and MVB12B proteins frequently
exhibited multiple banding patterns on SDS-PAGE gels
suggestive of protein phosphorylation. Consistent with
this observation, multiple threonine and serine phosphor-
ylation sites in both MVB12A and MVB12B were identified
by mass spectrometry (Figure 7C, Table S2, and
Figure S6). To begin to test whether MVB12 phosphoryla-
tion was functionally important, we created two different
Cell Host & Microbe
Composition of Human ESCRT-IFigure 6. siRNA Depletion of MVB12 Proteins Inhibits HIV-1 Infectivity and Viral Maturation
(A) siRNA depletion of endogenous MVB12A (upper panel) and overexpressed MVB12B (lower panel). siRNA names denote the first nucleotide tar-
geted by the 21 nt (19 nt + TT overhang) siRNA duplexes.
(B) (Upper panel) Reduction in HIV-1 infectivity upon depletion ofMVB12 proteins. (Middle panel) Viral particle release as analyzed bywestern blotting.
(Lower panel) cellular MA and CA expression levels. Error bars represent standard deviations in multiple repetitions of the experiment (n = 6).
(C) EM analysis and quantification of viral maturation phenotypes from control cells (white bars) or from cells depleted of MVB12A (gray) or MVB12B
(black). EM images show representative examples of mature and condensed phenotypes, together with a continuum of amorphous phenotypes. Per-
centageswere derived by scoring >40 randomly selected virions released under each condition. Note that ‘‘condensed’’ phenotypesmay simply arise
when mature conical cores are imaged in cross-section. Scale bars are 10 nm.expression constructs for mutant MVB12A proteins that
lacked phosphorylation sites. The MVB12A 5A construct
had alanine mutations in place of the five confirmed
MVB12A phosphorylation sites, and the MVB12A 9A con-
struct had four additional mutations that corresponded to
mapped phosphorylation sites in MVB12B (Figure 7C,
lower two panels). Both mutant MVB12A proteins
expressed well (Figure 7D, lower right panel) and formed
stable ESCRT-I complexes (data not shown), indicating
that the mutations did not grossly alter MVB12A folding
or ESCRT-I association. Nevertheless, the mutations
attenuated the ability of overexpressed MVB12A to block
HIV-1 infectivity (Figure 7D, left panel), virion release
(upper right panel), and Gag processing (middle right
panel). Thus, MVB12A phosphorylation is not required
for ESCRT-I complex formation, but is required for effi-
cient MVB12A-mediated dominant inhibition of HIV-1
release and infectivity. Importantly, this is also the first
indication that kinases (and perhaps also phosphatases)
are involved in the ESCRT pathway.
DISCUSSION
Our studies reveal that MVB12 proteins are previously
unidentified subunits of human ESCRT-I. Closely related
MVB12 orthologs are conserved across metazoa, and
vertebrates express two distinct, but related, MVB12
paralogs (MVB12A and MVB12B). Two other ESCRT-ICsubunits, TSG101 and VPS28, lack obvious paralogs,
whereas mammals express four distinct, but related,
VPS37 proteins from different genes (VPS37A-D). Soluble
ESCRT-I complexes contain single copies of each of the
four different subunit types (TSG101, VPS28, VPS37,
and MVB12). Hence, the different known VPS37 and
MVB12 paralogs can combine to produce up to eight
different ESCRT-I variants, and we find that all possible
combinations can form stable complexes in cells. Human
cells also appear to express (1) two alternative VPS28
transcripts with different C-termini, one of which has
a TSG101-binding PSAP motif (Gill et al., 2007a; Martin-
Serrano, personal communication), and (2) a truncated
splice isoform of MVB12B that lacks ESCRT-I binding
activity. Thus, human ESCRT-I is best described as a het-
erogeneous family of related complexes. It is reasonable
to expect that the different ESCRT-I isoforms will perform
distinct, but possibly overlapping, functions. Obvious
possible ways in which the different ESCRT-I isoforms
could vary include expression patterns, cellular localiza-
tion, cargo selection, biological functions, and/or mecha-
nisms of regulation.
Yeast Mvb12p (12 KDa) is much smaller than both
MVB12A (29 KDa) and MVB12B isoform I (36 KDa), and
there are no significant regions of sequence similarity.
Nevertheless, we believe that the human MVB12 proteins
are the functional orthologs of yeast Mvb12p, as both
the yeast and human proteins function as stable fourthell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc. 49
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Composition of Human ESCRT-IFigure 7. MVB12 Overexpression Inhibits
HIV-1 Release, Infectivity, and Processing
(A) Reductions in HIV-1 release and infectivity
upon overexpression of MVB12A or MVB12B.
Left panel shows infectivity data. Upper right
panel is a western blot showing levels of
HIV-1 particles released into the supernatant
(anti-MA and anti-CA detection). Middle right
panel shows cellular expression levels and
proteolytic processing of Gag (anti-MA and
anti-CA detection). Lower right panel shows
cellular MVB12 expression levels (anti-Myc).
Western blotting data from lane 2 in this
figure and in Figure 7Dwere quantified to deter-
mine changes in protein levels upon MVB12A
overexpression (relative to control conditions,
lanes 1): Cell-associated Gag protein, 71 ±
8%; cell-associated CA + MA proteins, 11 ±
3%; virion-associated CA + MA proteins,
16 ± 5%. Error bars represent standard devia-
tions in multiple repetitions of the experiment
(n = 6).
(B) EM analyses showing aberrant particles
released from 293T cells depleted of MVB12A
(upper panel) or TSG101 lower panel.
(C) Summary of the mapped (black) or putative
(white) phosphorylation sites on MVB12A and
MVB12B (upper two panels) and MVB12A 5A
and 9A mutant constructs (lower two panels).
(D) MVB12A phosphorylation mutations abro-
gate dominant inhibition of HIV-1 release and
infectivity. Left panel shows infectivity data.
Error bars represent standard deviations in
multiple repetitions of the experiment (n = 6). Upper right panel is a western blot showing levels of HIV-1 particles released into the supernatant
(anti-MA and anti-CA detection). Middle right panel shows cellular expression levels and proteolytic processing of Gag (anti-MA and anti-CA detec-
tion). Lower right panel shows cellular MVB12A expression levels (anti-Myc).subunits of ESCRT-I. Moreover, bothMvb12p andMVB12
bind the ESCRT-I core region, although one group has
reported that Mvb12p binds Vps23p/TSG101 (Chu et al.,
2006), whereas another reported that it binds Vps37p
(Curtiss et al., 2007). This behavior seems consistent
with our observations that (1) the binary TSG101/VPS37
complex forms the minimal binding site for human
MVB12 proteins, implying that they may contact both
TSG101 and VPS37, and (2) at least two different regions
of the MVB12 proteins contact ESCRT-I. Moreover, al-
though the precise functions of both Mvb12p and
MVB12 proteins remain to be established,Mvb12p knock-
outs exhibit attenuated and unusual phenotypes as com-
pared to knockouts of the other yeast ESCRT-I subunits,
suggesting that Mvb12p may play a functionally unique
or regulatory role in yeast ESCRT-I function (Chu et al.,
2006; Curtiss et al., 2007; Oestreich et al., 2007). Similarly,
HIV-1 release and infectivity are less severely blocked by
MVB12 depletion than by TSG101 depletion, and there are
also significant phenotypic differences between the two
conditions. Finally, while our manuscript was under re-
view, Hurley and colleagues reported the crystal structure
of the heterotetrameric yeast ESCRT-I core complex,
which revealed a highly elongated complex in which
a globular ‘‘headpiece’’ sits at one end of an extended50 Cell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc.‘‘stalk’’ (Kostelansky et al., 2007). Our studies are in excel-
lent agreement with their structural and biochemical anal-
yses because they find that yeast ESCRT-I is a 1:1:1:1
complex in which the Mvb12p subunit binds the binary
Vps23p/TSG101-Vps37p complex to form the ESCRT-I
stalk.
Although our experiments establish that the soluble en-
dogenous ESCRT-I complexes extracted from human
cells are 1:1:1:1 complexes of TSG101:VPS28:VPS37:
MVB12 (here termed ESCRT-I ‘‘monomers’’), several
important issues still surround ESCRT-I localization and
oligomerization within cells. First, self-association of
ESCRT-I and its Vps23p/TSG101 subunit has been
reported (Chu et al., 2006; Martin-Serrano et al., 2003;
von Schwedler et al., 2003), and we also observed that
a small population of stable ESCRT-I dimers formed under
overexpression conditions. Second, a recent immunoloc-
alization study reported that the majority of ESCRT-I is
found in close juxtaposition with cellular membranes
(Welsch et al., 2006), whereas all of our analyses were
performed on soluble ESCRT-I complexes. We therefore
considered the possibility that the Triton detergent used
during cell lysis might have altered ESCRT-I oligomeriza-
tion or membrane association. This was not the case,
however, as the soluble endogenous ESCRT-I monomer
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in isotonic saline lacking detergent and the soluble
ESCRT-I in these crude lysates was analyzed immediately
by gel filtration chromatography (data not shown). We
therefore conclude that under steady state conditions,
human ESCRT-I is a monomer, and any oligomeric or
membrane associations must be weak at best. These
properties may well change, however, when ESCRT-I is
transiently recruited to sites of vesicle formation or virus
budding. Indeed, we observe strong endosomal mem-
brane localization of all of the different ESCRT-I subunits,
including MVB12A, in the absence of VPS4 ATPase activ-
ity, and these membrane-associated multiprotein associ-
ations are highly resistant to detergent extraction.
Our data are consistent with the idea that human
MVB12 is an important, but not absolutely essential, sub-
unit of human ESCRT-I. Importantly, HIV-1 budding and
assembly are perturbed when cellular MVB12 levels are
altered, indicating that MVB12 functions in HIV-1 release.
Specifically, MVB12 protein depletion caused moderate
(2- to 5-fold) decreases in viral infectivity with correspond-
ing increases in the production of electron-dense, amor-
phous particles. MVB12 protein overexpression inhibited
HIV-1 release and infectivity even more severely (12- to
15-fold), and complete inhibition requiredMVB12 proteins
that could bind ESCRT-I and be fully phosphorylated.
MVB12 overexpression again altered the phenotype of
viral assembly, in this case leading to the accumulation
of membrane-tethered, immature particles that remained
associated with the cell surface. Remarkably, MVB12
overexpression also dramatically reduced the accu-
mulation of intracellular Gag processing intermediates
(Figure 7A, middle right panel, lanes 2 and 4). TSG101
overexpression also alters the processing pattern of cell-
associated Gag, but in that case Gag processing is de-
layed, resulting in an appreciable buildup of the CA-SP1
and p41 processing intermediates (e.g., Figure 7A, middle
right panel, lane 6). Thus, high levels of both MVB12 and
TSG101 alter the normal coupling between Gag process-
ing and virus budding, thereby changing the range of cell-
associated Gag processing intermediates, but the precise
changes in Gag processing are different in the two cases.
Finally, we speculate thatMVB12 proteins will also func-
tion in the sorting of cellular protein cargoes at themultive-
sicular body and that they may play a unique role in
ESCRT-I function, perhaps in helping to regulate confor-
mational changes, complex release, or other essential
ESCRT-I transformations. Evidence in support of a unique
regulatory role for MVB12A includes (1) indications that
the yeast homolog, Mvb12p, also regulates various differ-
ent ESCRT-I activities (Chu et al., 2006; Curtiss et al.,
2007; Oestreich et al., 2007), (2) the series of distinctive
viral assembly phenotypes that occur in response to
altered MVB12 levels, including aberrant virion morphol-
ogies and unusual changes in the normal coupling
between Gag processing and virus budding, and (3) the
extensive number of MVB12A and MVB12B phosphoryla-
tion sites, which suggests the possibility of posttransla-
tional regulation. More detailed mechanistic studies ofCESCRT-I are clearly warranted, and such studies should
be facilitated by the identification of MVB12 as the last
remaining core subunit of metazoan ESCRT-I and by the




293T cells and HOS-pBABE-puro cells (generously supplied by Dr.
Nathan Landau through the AIDS Reference and Reagent Program,
cat. no. 3517) were maintained in DMEM supplemented with 10%
FCS. K562 cells were maintained in RPMI-1640 medium supple-
mented with 10% FCS. To assay HIV-1 production, 5 3 105 293T
cells/well (6-well plate) were transfected with 2 mg R9 proviral HIV-1
expression plasmid (Garrus et al., 2001; Swingler et al., 1997). For
immunofluorescence experiments, HOS cells were seeded onto
coverslips, cotransfected at 50%–60% confluence, and imaged as
described in the caption to Figure S5.
Expression Plasmids
Expression plasmids used in this study are summarized in Table S3.
ESCRT-I Complex Purification
For small scale purifications, 293T cells were seeded (33 106 cells/55
cm2 dish) and cotransfected with 3 mg each of ESCRT-I expression
plasmids using polyethylenimine (25,000 KDa; Polysciences, Warring-
ton, PA) as described (Durocher et al., 2002). Cells were harvested
48 hr posttransfection by inclubation in 300 ml lysis buffer (LB: 50
mM Tris [pH 7.4], 150 mM NaCl) supplemented with proteinase inhib-
itor cocktail (Sigma) and 1% Triton X-100. Lysates were clarified by
centrifugation (18,0003 g, 10 min, 4C) and incubated with Strep-
Tactin Sepharose (40 ml slurry, IBA GmbH, Gottingen Germany, 2 hr,
4C). The matrix was washed 4 times in wash buffer (WB: 20 mM
Tris [pH 7.4], 150 mM NaCl) supplemented with 0.1% Triton X-100,
and purified ESCRT-I complexes were eluted with 2.5 mM desthiobio-
tin in WB. Typical yield: 30 mg ESCRT-I.
For large-scale preparations (e.g., for analytical ultracentrifugation
experiments), this basic procedure was scaled up 200-fold with the
following modifications: (1) douncing (1003) was used to promote
cell lysis, (2) ESCRT-I complexes were affinity purified on a 5 ml
Strep-Tactin Sepharose column (detergent-free LB washes), and (3)
affinity purified ESCRT-I complexes were concentrated to 2 ml using
a Vivaspin 2 concentrator (Vivascience Ltd., 30,000 MW cutoff) and
purified by gel filtration in LB (16/26 Superdex 200 column in LB lacking
detergent). Recombinant ESCRT-I complexes eluted in two peaks,
a major peak (MWapp 280 KDa) and a minor peak (MWapp 570
KDa). This procedure typically yielded 1 to 2 mg purified ESCRT-I (ma-
jor peak).
Gel Filtration Analyses of ESCRT-I Complexes
K562 or 293T cells expressing endogenous or exogenous ESCRT-I
were suspended in PBS ± 0.1% Triton X-100 and proteinase inhibitor
cocktail and lysed by douncing. Lysates were clarified by centrifuga-
tion (18,000 3 g, 10 min, 4) and chromatographed on a calibrated
Superdex 200 gel filtration column. Fractions were collected, and
ESCRT-I proteins were detected by western blotting following
trichloroacetic acid precipitation and SDS-PAGE.
Equilibrium Sedimentation Analyses
The major and minor ESCRT-I gel filtration peaks were collected
separately and concentrated. Equilibrium sedimentation experiments
were performed in an Optima XL-I centrifuge (Beckman Coulter)
at concentrations of 3.6 and 1.8 mM in 50 mM Tris$HCl (pH 7.5),
150 mM NaCl, 4C. The major (monomeric) ESCRT-I complex was
centrifuged at two speeds (12,000 and 16,000 RPM), and the fourell Host & Microbe 2, 41–53, July 2007 ª2007 Elsevier Inc. 51
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(Cole, 2004). Analysis of the ESCRT-I dimer is described in Figure S4.
ESCRT-I Binding Assays
Soluble GST and GST-p6Gag fusion proteins were expressed in E. coli
(Garrus et al., 2001). Fifty milliliter cultures were pelleted, resuspended
in 4 ml binding buffer (150 mM NaCl, 1% NP-40, 10% glycerol, 1 mM
DTT, 50 mM Tris [pH 8.0]) and lysed by lysozyme treatment (1.2 mg)
and sonication (33). For each binding reaction, protein from 10 ml
soluble E. coli extract was captured on 15 ml glutathione-Sepharose
slurry (Amersham Biosciences). Recombinant HIS-V5-HRS was
expressed in Sf21 insect cells following manufacturer’s instructions
(BaculoDirect, Invitrogen). Sf21 infected cells were resuspended in
LB with 1% Triton X-100 and protease inhibitors, and lysed by dounce
homogenization. For each binding reaction, protein from 10 ml soluble
Sf21 extracts was captured on 15 ml anti-V5 antibody conjugated resin
slurry (Sigma). To assess binding, 0.1 nmol purified recombinant
ESCRT-I complex was incubated with 1.0 nmol of immobilized
GST-p6Gag, V5-HRS, or control proteins (1 hr, 4C in WB supple-
mented with 0.1% Triton X-100). Unbound ESCRT-I was removed by
washing with WB, and bound ESCRT-I proteins were released by boil-
ing in SDS-PAGE loading buffer and analyzed by 12%SDS-PAGE with
Coomassie staining or western blotting using rabbit anti-FLAG anti-
body (1:1000, Sigma).
Antibody Production
Antibodies to affinity-purified recombinant GST-MVB12A and OSF-
MVB12B were raised in New Zealand White Rabbits (Covance, Inc.).
MVB12A antibodies were affinity purified by binding to recombinant
OSF-MVB12A1–191, as described (von Schwedler et al., 2003).
Assays for HIV Release and Infectivity
HIV-1 infections were initiated by transfection of the proviral HIV-1 R9
construct, with cell- and virion-associated Gag proteins detected by
western blotting and viral titers measured using single-cycle MAGIC
assays as described previously (Garrus et al., 2001). Myc-tagged
ESCRT-I proteins were analyzed by western blotting (1:3000 mouse
anti-Myc 9E10, Covance).
Electron Microscopy
Procedures for obtaining EM images of free and cell-associated thin-
sectioned virions were as described previously (von Schwedler et al.,
1998), except that the samples were fixed with 2.5% gluteraldehyde/
1% paraformaldehyde and dehydrated with an ethanol series.
Supplemental Data
The Supplemental Data include three supplemental tables and six sup-
plemental figures and can be found with this article online at http://
www.cellhostandmicrobe.com/cgi/content/full/2/1/41/DC1/.
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